Myeloproliferative Neoplasms

Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib.

Serum ferritin at baseline was a predictor for week 24 transfusion independence response in patients with myelofibrosis receiving momelotinib according to findings from an analysis of data from the phase 3 SIMPLIFY trials.

Treatment with pacritinib, when administered at 200 mg twice daily, had a comparable safety profile to best available therapy in patients with cytopenic myelofibrosis, including those with severe thrombocytopenia.

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

Paul M. Ness, MD, discusses the goal of the Hemanext ONE® blood storage system and the potential benefit of this approach for those with myelodysplastic syndrome and other conditions that require transfusions.

Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.

The FDA has extended the review period for the new drug application for pacritinib as a treatment for adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis and severe thrombocytopenia with a baseline platelet count of 50 x 109/L.

David Sallman, MD, discusses incorporating mutational testing of patients with myelodysplastic syndrome into clinical practice, and strategies that can be utilized to treat this population.

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

The FDA has approved ropeginterferon alfa-2b-njft for use as a treatment in patients with polycythemia vera.

Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Treatment with ruxolitinib was not found to carry an increased risk of secondary malignancies in patients with polycythemia vera.

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis.

The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide.

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.

The hallmarks of myelofibrosis—including clonal myeloproliferation, bone marrow fibrosis, anemia, splenomegaly, and constitutional symptoms—are associated with risk of morbidity and mortality; however, the recent advent of novel combinations and sequencing strategies have built on the foundation of care established with JAK2 inhibitors.

The investigational JAK inhibitor momelotinib is effective at treating anemia in patients with myelofibrosis, resulting in improved rates of transfusion independence compared with ruxolitinib.

Although there are several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.